Smurf2 Gene Expression in Urinary Tract Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05134623

Recruitment Status : Unknown

Verified November 2021 by Ziv Hospital.
Recruitment status was: Not yet recruiting

First Posted : November 26, 2021

Last Update Posted : December 16, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Azrieli Faculty of medicine, Bar Ilan University, Safed, IL

Information provided by (Responsible Party):

Ziv Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	January 2023
Estimated Study Completion Date :	December 2023

Publications:

Manikoth Ayyathan D, Koganti P, Marcu-Malina V, Litmanovitch T, Trakhtenbrot L, Emanuelli A, Apel-Sarid L, Blank M. SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis. Oncogene. 2020 Apr;39(16):3396-3410. doi: 10.1038/s41388-020-1226-3. Epub 2020 Feb 26.

To Top